Study Description
The purpose of this study is to continue to assess safety and tolerability, and to allow
continued access to study treatment for subjects already receiving spartalizumab as
single agent or in combination with other study treatments.
Interventions
PDR001
Eligibility Criteria
Inclusion Criteria:
- Subject is currently enrolled in a pre-defined Novartis-sponsored study and is
receiving spartalizumab as single agent or in combination with other study
treatment,
- Subject is currently deriving clinical benefit from the study treatment, as
determined by the investigator.
Other protocol defined inclusion criteria may apply
Exclusion Criteria:
- Subject has been permanently discontinued from spartalizumab in the parent protocol
for any reason other than enrollment in the Roll over Study
- Subject does not meet the criteria specified in the parent protocol criteria for
continued study treatment.
Worldwide Contacts
If the location of your choosing does not feature any contact detail, please reach out using the information below.